The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

doi:10.3324/haematol.2017.179895

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Haematologica - 1 May 2018

Schneeweiss Mathias, Peter Barbara, Bibi Siham, Eisenwort Gregor, Smiljkovic Dubravka, Blatt Katharina, Jawhar Mohamad, Berger Daniela, Stefanzl Gabriele, Herndlhofer Susanne, Greiner Georg, Hoermann Gregor, Hadzijusufovic Emir, Gleixner Karoline V, Bettelheim Peter, Geissler Klaus, Sperr Wolfgang R, Reiter Andreas, Arock Michel, Valent Peter

Abstract excerpt

Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib. Clinical problems in systemic mastocytosis arise from mediator-related symptoms and/or organ destruction caused by malignant expansion of neoplastic mast cells and/or other myeloid cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mast Cells

Share to Mastocytosis, Systemic

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 29439183
DOI: 10.3324/haematol.2017.179895
PMCID: PMC5927976

Genes

DCC
KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.PMID 29439183Read ↗

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.Semantic proximity Read ↗

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Recent advances in the understanding and therapeutic management of mastocytosisSemantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.Semantic proximity Read ↗

Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.Semantic proximity Read ↗

Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.Semantic proximity Read ↗

Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Precision Medicine in Systemic Mastocytosis.Semantic proximity Read ↗

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Semantic proximity Read ↗

How I treat patients with advanced systemic mastocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.